

Cost-Effectiveness Analysis of a Randomized Study of Depression Treatment Options in Primary Care Suggests Stepped-Care Treatment may Have Economic Benefits



INSTITUTE OF
HEALTH ECONOMICS
ALBERTA CANADA

Name: Charles Yan, PhD;
Katherine Rittenbach, PhD;
Sepideh Souri, MSc; and
Peter H. Silverstone , MB BS, MD, FRCPC

Event: 2019 CADTH Symposium, Edmonton

Disclosure and Acknowledgements

- Financial support for this study was provided entirely by a financial contribution from Alberta Health Services (AHS).
- This study was supported by the Addiction & Mental Health Strategic Clinical Network (A&MH SCN), AHS.
- We would like to thank
 - the Primary Care Networks (PCN) for participating in the clinical trial.
 - Christopher McCabe for comments on previous draft; and
 - Deena Hamza, Stefanie Kletke and Tennile Tavares for research assistance.

Presentation Outline

- Background
- Objectives
- Analytic model
- Results
- Lessons/conclusions:
 - While more work is required to identify the most clinically effective versions of a stepped-care pathway (SCP), our findings suggest that the SCP for depression may have substantial potential to improve healthcare system value.

Background

- Some studies suggested that a stepped-care pathway (SCP) is an effective approach to depression management in primary care.
 - The SCP model starts from self-identification of depression risk and severity.
 - Treatment guidelines are then given based on the screening results
 - both antidepressant medication and psychosocial interventions
- However, there is little information regarding the cost-effectiveness of a specific SCP.

Background (Cont'd)

- a RCT conducted in Alberta to assess the impact of a SCP, compared to other treatment options
 - 1,400 patients
 - 12-week follow-up
 - 4 treatment arms:
 1. a standard care (SC);
 2. a treatment-as-usual (TAU);
 3. an online cognitive behavioural therapy (CBT);
 4. a stepped-care pathway (SCP).
 - Outcomes: PHQ-9, EQ-5D
 - The SCP was developed in Calgary
- Trial registration: This trial was registered with Clinical Trials database.
 - Identifier: NCT01975207

Objective

- We conducted an economic analysis to:
 - To estimate medical costs of depression, and
 - To determine whether the SCP was cost-effective
- Study population:
 - The adults who visited their primary care physicians and were screened for depression;
 - Subgroup: screened positive for depression symptoms (PHQ-9 score over 10 at baseline)
- Interventions:
 - The analysis compared SCP with other 3 treatments

Methods: data collection

- EQ-5D
 - Baseline, and
 - 12 weeks post-randomization
- Costs of physician, outpatient, and inpatient services:
 - 12 weeks pre-randomization,
 - 12 weeks post-randomization, and
 - from 12 weeks to 1-year post-randomization.
 - Data sources:
 - provincial healthcare administrative databases


Methods: statistical analysis

- Intention-to-treat (ITT) approach was used
 - helps avoid bias
- multiple imputation:
 - Handle Missing data;
- OLS regression and generalized linear model (GLM):
 - Adjust for imbalances in baseline characteristics
- one-way ANOVA test:
 - Test the difference between intervention arms
- pairwise comparison of mean:
 - Test the difference between each pair of intervention arms
- mean-comparison t-test :
 - Test the difference between baseline and 12-week post randomisation for each intervention arm


Results: effectiveness

- Significant improvement in PHQ-9 and EQ-5D from baseline to 12-week post randomisation in all arms
 - In all participants, the mean change
 - 0.72 (95% CI 0.61– 0.82) in PHQ-9 and
 - 0.024 (95% CI 0.021 – 0.027) in EQ-5D
 - In depressed participants (PHQ-9 > 10 at baseline), the mean change
 - 4.8 (95% CI 4.58– 5.02) in PHQ-9 and
 - 0.103 (95% CI 0.092 – 0.115) in EQ-5D
- However, there was no significant difference between groups.

CE Results: In all participants



CE Results: In depressed subgroup



Number of participants receiving physician, outpatient, and/or inpatient services

Arm	No services	Physician only	Physician + outpatient	Physician + inpatient	Physician + outpatient + inpatient	Total
All participants						
Arm 1 (SC)	4 (1.0%)	179 (43.4%)	176 (41.99%)	3 (0.73%)	53 (12.9%)	412
Arm 2 (TAU)	8 (2.0%)	160 (40.3%)	160 (39.80%)	2 (0.5%)	69 (17.4%)	397
Arm 3 (iCBT)	4 (1.0%)	188 (45.3%)	164 (37.83%)	7 (1.69%)	59 (14.2%)	415
Arm 4 (SCP)	3 (1.6%)	75 (41.0%)	88 (48.08%)	na	17 (9.3%)	183
Depressed subgroup						
Arm 1 (SC)	0 (0%)	21 (37.5%)	28 (50%)	na	7 (12.5%)	56
Arm 2 (TAU)	2 (3%)	21 (31.8%)	35 (53%)	na	8 (12.1%)	66
Arm 3 (iCBT)	0 (0%)	22 (44%)	23 (46%)	na	5 (10%)	50
Arm 4 (SCP)	0 (0%)	12 (35.3%)	18 (52.9%)	na	4 (11.8%)	34

Discussion

- Our study found no significant difference between SCP, SC, TAU and iCBT in terms of depression symptom reduction and EQ-5D improvement.
- Interestingly, our CEA revealed SCP is more cost-effective than the other alternatives.
- A relatively small portion of patients received hospital stays in SCP group.
 - Our finding may be driven by this, given that hospital costs are
 - 8 times outpatient costs and
 - 12 times physician costs
- While more work is required to identify the most clinically effective versions of a SCP, our findings suggest
 - that the care pathway may have substantial potential to improve healthcar system value.

Limitations

- The sample size was much smaller in the particular SCP group than the others.
- The effectiveness data was derived from 12-week trial and then assumed the observed quality of life at 12-week would be maintained until one year.
- The set-up costs SCP were not included in the economic analysis.



INSTITUTE OF
HEALTH ECONOMICS
ALBERTA CANADA



cyan@ihe.ca



1.780.448.4881



www.ihe.ca